Lonicera

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lonicera

Property Description
Active Ingredients Desogestrel, Ethinyl Estradiol
Form Tablet (Oral Dosage Form)
Pharmacological Class Combined Oral Contraceptive (COC)
Common Use Prevention of Pregnancy (Contraception)
Origin Synthetic Steroidal Hormones

What Type of Birth Control is Lonicera?

Lonicera is defined as a Combined Oral Contraceptive (COC), a prescription-only hormonal birth control method. Defined as an oral dosage form, the product is administered as a tablet and belongs to the pharmacological class of Estrogens/Progestins. Its combined composition is clinically recognized for providing a highly effective method of birth control. As a combination product, it is routinely prescribed to women of reproductive age seeking a reversible and dependable method of planned contraception. Other popular branded preparations sharing this exact combination include Ortho-Cept and Desogen, illustrating its established role in gynecological care.

What Hormones Are in Lonicera?

The composition of Lonicera involves a combination product containing the synthetic hormones Desogestrel and Ethinyl Estradiol. Ethinyl Estradiol functions as the estrogen component, while Desogestrel is the progestin component, pharmacologically characterized as a third-generation progestogen. All active ingredients are purely synthetic steroidal compounds. The tablets utilize various solid pharmaceutical excipients as the structural base, necessary for forming the dosage unit and supporting the oral route of administration, a standard practice for many combined hormonal pills.

What is Lonicera's Main Purpose?

The primary purpose of Lonicera is the reliable prevention of pregnancy (contraception). This function is achieved through multiple, coordinated hormonal actions. The main action involves the active ingredients working to ensure the inhibition of ovulation—stopping the monthly release of an egg from the ovary. Supplementary effects include modifying the reproductive environment by thickening the cervical mucus and altering the endometrium (uterine lining), actions which are foundational to the efficacy of the COC class. These scientifically supported effects provide dependable control over reproductive health in a typical use scenario.

Regulatory References

  1. Combined Oral Contraceptives

What side effects are possible with Lonicera?

Possible Side Effects and Safety Information

The safety profile of Lonicera, as documented in regulatory sources, focuses on classifying known or potential adverse reactions and establishing specific restrictions for use.

Adverse Reaction Scope

Adverse reactions are primarily categorized by frequency classification (e.g., Very Common, Common, Uncommon, Rare, Very Rare, or Not Known) and by System Organ Class (SOC). The major organ systems involved in documented adverse events include Gastrointestinal disorders, Nervous system disorders, Skin and subcutaneous tissue disorders, and Immune system disorders.

Serious Adverse Reactions requiring immediate regulatory reporting and investigation include severe hypersensitivity reactions (such as anaphylaxis) and potential signs of Hepatobiliary disorders (severe liver function abnormalities).

Safety Restrictions and Monitoring

Safety documents list specific limitations and cautions for Lonicera use:

  • Contraindications: Use is restricted in individuals with a confirmed hypersensitivity to the active substance or any excipients.
  • Special Caution: Regulatory documents advise caution in patients with pre-existing hepatic impairment and often recommend regular monitoring of liver function tests (LFTs) during prolonged administration.
  • Vulnerable Populations: Safety data for pediatric populations (e.g., children under 12 years) is often considered not established, requiring particular regulatory surveillance.
  • Coagulation Risk: A specific warning pertains to Lonicera's potential to affect blood clotting. Caution is advised, and discontinuation is typically required before scheduled surgical procedures to mitigate the risk of extra bleeding.

This regulatory framework organizes the official safety information, ensuring that known risks, especially rare but serious events, are identified and systematically monitored through continuous regulatory surveillance.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents explicitly define the expected presentations and necessary actions following the ingestion of an excessive quantity of Lonicera. The documented clinical manifestations reported in overdose scenarios involve the gastrointestinal and reproductive systems. These presentations commonly include nausea, vomiting, and vaginal bleeding (or withdrawal bleeding).

A crucial regulatory finding is that acute overdose of combined oral contraceptives is generally not associated with serious harmful effects or life-threatening toxicity. Nevertheless, immediate action is officially mandated: individuals must seek immediate medical attention or contact a poison control center immediately for professional assessment following any suspected overdose.

In terms of clinical management, regulatory authorities state that no specific antidote is known for overdose with this medication. Treatment is therefore required to be symptomatic and supportive, aiming to manage the manifestations until they fully resolve. A specific population consideration noted in official documents is the potential for slight vaginal bleeding to occur in young girls (prepubertal females) who have ingested the medication. This structure dictates that the response must be professional consultation and supportive care.

Therapeutic Uses of Lonicera

What Lonicera Treats: Main Uses and Benefits

Lonicera is primarily utilized for reliable prevention of pregnancy, providing essential support for planned reproductive control in women of childbearing age seeking a reversible method of fertility management. This medication is also commonly used to help manage specific gynecological and dermatological symptoms related to systemic imbalance.

Regulation of Painful and Heavy Menstrual Cycles

This medication is frequently prescribed to address symptoms related to menstrual cycle dysfunction, specifically severe pain (dysmenorrhea) and excessive blood loss (menorrhagia). The therapeutic support contributes to establishing a predictable, manageable bleeding schedule, assisting with alleviating the disruptive impact of heavy or painful periods on daily functioning and quality of life. The combined hormones may assist with easing symptoms associated with conditions like endometriosis.

“Lonicera is considered relevant for managing symptoms that interfere with daily comfort, particularly those linked to cyclical discomfort and hormonal imbalances.”

Symptom Management for Skin and Hair Conditions

Lonicera is commonly used in addressing hormonally-mediated symptoms such as moderate acne and unwanted hair growth (hirsutism). The medication is commonly used to help manage symptoms related to heightened physiological activity, such as the androgen-related manifestations, supporting general well-being during symptomatic phases. Key indications include contraception, the management of heavy menstrual bleeding, painful periods, and moderate acne.


Quick Fact: Relief for Menstrual Distress

Lonicera is commonly applied in scenarios where symptoms related to physical discomfort become more disruptive during cyclical flare-ups, providing supportive relief that helps patients cope more steadily with symptom fluctuations.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility for Lonicera (Desogestrel/Ethinyl Estradiol)

Lonicera, a Combined Oral Contraceptive, is officially restricted to women of reproductive age who have reached menarche. Its eligibility profile is primarily defined by numerous absolute contraindications stipulated in government regulatory documents.

Populations Who Must Not Use Lonicera (Contraindicated)

Contraindication Category Examples of Prohibited Conditions
Thromboembolic Risk Current or history of venous or arterial thromboembolism (e.g., DVT, stroke, heart attack).
Cancer Risk Current or history of breast carcinoma or other known estrogen-dependent neoplasia.
Lifestyle/Age Risk Smoking in women over 35 years of age (absolute prohibition).
Organ Function Severe hepatic impairment or presence of hepatic adenomas/carcinomas.
Other Conditions Migraine with focal neurological symptoms (aura) or undiagnosed abnormal genital bleeding.

Age and Physiological Restrictions

Use is contraindicated in known or suspected pregnancy and is not generally recommended during breastfeeding. The medication is not indicated for post-menopausal women. While no formal studies exist on the effects of renal disease on the drug's disposition, severe hepatic impairment is an absolute exclusion criteria, limiting use based on organ function.

What should I know about interactions with other medicines?

Interactions with other medicines and products


Interacting Product Classes

The primary concern regarding Lonicera (Honeysuckle) interactions is linked to its potential pharmacodynamic effects, specifically the possibility of slowing blood clotting. This concern leads to interaction warnings involving medications that also inhibit coagulation or platelet aggregation.

Product Categories of Concern:

  • Anticoagulant and Antiplatelet Drugs: Lonicera may increase the risk of bruising and bleeding when used concurrently with medications that slow blood clotting. This includes prescription anticoagulants (like warfarin and direct oral anticoagulants), as well as nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and naproxen, which also possess antiplatelet activity.

Procedural and Timing Constraints

The potential for increased bleeding risk necessitates a procedural constraint related to surgery.

  • Surgery: Due to the risk of excessive bleeding during and after surgical procedures, it is advised that the use of Lonicera be discontinued at least two weeks prior to any scheduled surgery. This restriction is a precaution against potential additive anti-clotting effects.

No specific pharmacokinetic interactions, such as those involving cytochrome P450 enzymes or drug transporters, are consistently documented in authoritative regulatory-derived informational sources for Lonicera.

Mechanism of Action

Inhibiting Upstream Inflammatory Signaling

Lonicera's mechanism involves the inhibition and modulation of key transcription factors and kinases within cellular signaling pathways, primarily the NF-κB and MAPK cascades. By interfering with the activation of these molecular switches, the drug limits the genetic expression and subsequent production of pro-inflammatory mediators such as cytokines. This action leads to a core physiological effect of dampened, systemic hyper-inflammation and modulation of cellular immune responses.


Dual-Action Oxidative Stress Modulation

The drug engages a dual-action mechanism by functioning as a direct free radical scavenger and as an activator of the Nrf2 pathway. Nrf2 activation enhances the body's internal enzymatic defense against reactive oxygen species (ROS). This results in a consequential physiological outcome of increased cellular protection and tissue integrity against oxidative damage.


Direct Anti-Microbial Mechanism

A distinct mechanism involves the physical interaction of components with microbial membranes and cell walls. This structural interference with pathogens leads to increased permeability and leakage of intracellular contents, which results in the reduction of pathogenic load within the affected biological system, complementing the anti-inflammatory activity.

Dosage and Administration Information

How to Use Lonicera: Official Administration Guidelines

Lonicera, a combined oral contraceptive (COC) containing desogestrel and ethinyl estradiol, is administered via the oral route as a tablet. Its use is governed by a continuous cyclical schedule consisting of a specific sequence of tablets taken daily.


Official Dosing Regimen

The standard regimen for adults and postpubertal adolescents is a 28-day course. This course typically includes 21 active tablets, each containing 0.15 mg desogestrel and 0.03 mg ethinyl estradiol, followed by 7 inert (non-hormonal) tablets.


Timing and Schedule

Frequency: One tablet must be taken once daily (q.d.).

Timing: The tablet must be taken at the same time every day to maintain a consistent hormone level, with the interval between doses not exceeding 24 hours. The tablets should be taken in the specific sequential order indicated on the blister packaging.

Initiation: The first cycle can be started either on Day 1 of the menstrual period or on the first Sunday after the period begins. If the Sunday start method is used, the official instructions require the concurrent use of a non-hormonal barrier method for the first seven days of the initial cycle.

Continuation: A new 28-day pack must be started immediately after the last tablet of the previous pack, ensuring no gap days between cycles. This cyclical pattern continues for as long as the use is intended.


Population and Procedural Notes

The same dosing regimen applies to postpubertal adolescents. No specific dose adjustments are established in official documentation for patients with renal impairment. If one active tablet is missed, procedural instructions advise taking it as soon as remembered, even if this means taking two tablets at the same time, along with detailed instructions on when a barrier method is necessary for a short period. The tablets can be taken with or without food.

Recent Clinical Evidence

Lonicera: Recent Clinical Evidence

Evidence for use in Pregnancy Prevention (Contraception)

Lonicera was studied for its use in preventing pregnancy through Randomized Controlled Trials (RCTs) and observational cohorts. Research examined outcomes related to systemic or functional imbalance by measuring the incidence of pregnancy in the populations studied. Findings describe patterns observed in these studies, reporting measurements of pregnancy incidence that were related to contraceptive use compared to non-use. Observed outcomes also included the reported measurement of a more predictable bleeding schedule. What remains uncertain is the full characterization of long-term effects, as follow-up durations were limited in the initial trials. Data for certain groups, such as those with specific concurrent medical conditions, may also remain insufficient.


Evidence for use in Managing Menstrual Cycle Symptoms

Lonicera was evaluated in trials assessing short-term or episodic symptom patterns in women presenting with outcomes related to physical discomfort and excessive blood loss. Research examined these outcomes by using standardized scores to monitor symptom intensity and blood loss volume. Studies observed how these symptoms evolved over defined time intervals. Findings describe patterns observed in the studies, including reported changes in pain severity scores and observed measurements of blood loss volume during the study period. This research is part of the broader evidence landscape by exploring outcomes reflecting daily functioning during the menstrual cycle.


Evidence in Other Areas and Uncertainties

Lonicera was also studied for its potential role in conditions associated with acute or disruptive episodes, such as hormonally-mediated skin and hair outcomes. Outcomes monitored physiological strain using measurements like acne lesion counts and hair growth severity scales. Studies report findings that indicate a progressive change in both acne severity scores and hair growth measurements over a period of many months. Comparative evidence is lacking against all individual alternatives for specific indications, and long-term effects related to the durability of symptom change after stopping the medication are not fully established.

Key Studies & References Desogestrel and Ethinyl Estradiol (Oral Route) - NIH MedlinePlus Drug Information

Frequently Asked Questions (FAQ)

Common questions about Lonicera (FAQ)


Q: How quickly does Lonicera usually start working?

A: Official administration instructions state that if administration begins on the Sunday following the start of menstruation, the use of a non-hormonal barrier method is advised in official instructions for the initial seven days of that first cycle. This timeframe is described in official documentation as the period during which contraceptive effectiveness is established.


Q: Can Lonicera be taken long-term?

A: Continuous, long-term administration is required to maintain the drug’s primary effectiveness for pregnancy prevention. Regulatory documents state that use of this class of medicine over many years has been associated with an increased risk for certain conditions, such as venous thromboembolism (blood clots) and hepatic neoplasia (liver growths). Regulatory documentation requires continuous assessment by a healthcare provider for ongoing safety.


Q: Is Lonicera safe to use while breastfeeding?

A: Official labeling states that Lonicera is not generally recommended while breastfeeding. Regulatory documents indicate that the use of this type of medicine has been associated with potential adverse effects on the infant and may also reduce the production of breast milk.


Q: Are there any specific foods or drinks I need to avoid when using Lonicera?

A: The tablets can generally be taken with or without food. However, some regulatory documents caution that grapefruit juice may cause interactions to occur with certain medications and note that its concurrent use is usually not recommended.


Q: Can Lonicera cause changes in weight?

A: According to official regulatory safety data, increased weight is listed among the common reported adverse reactions for this class of medicine. In contrast, decreased weight is reported as an uncommon or rare adverse reaction.


Q: What happens if I suddenly stop taking Lonicera?

A: Stopping Lonicera results in the immediate cessation of its contraceptive effect, and contraceptive protection cannot be assumed. Additionally, regulatory documents note that a temporary return to infertility is possible after stopping the treatment.


Q: Is Lonicera a controlled substance?

A: Lonicera is classified as a prescription-only Combined Oral Contraceptive. It is not designated as a controlled substance under regulatory frameworks such as the U.S. Controlled Substances Act.


Q: Can Lonicera be taken during pregnancy?

A: Lonicera is contraindicated (must not be used) in known or suspected pregnancy. Official regulatory documents classify it as Pregnancy Category X, meaning its use is prohibited during gestation.


Q: What should I do if I miss a dose of Lonicera?

A: The detailed instructions for a missed dose vary depending on the product’s specific formulation and the number of tablets missed. As detailed administration protocols are essential for maintaining contraceptive efficacy, patients are advised to consult the specific Patient Information Leaflet included with the pack or contact a healthcare provider for the precise procedure.


Q: What should I look out for that indicates a serious reaction to Lonicera?

A: Official regulatory warnings describe potential signs of serious reactions, such as blood clots (e.g., sudden chest or leg pain, or difficulty breathing), stroke (e.g., sudden severe headache or trouble speaking), and serious liver problems (e.g., yellowing of the skin/eyes or upper stomach pain).


Q: Can Lonicera be taken on an empty stomach?

A: Official administration instructions indicate that the tablets can be taken either with or without food. Taking the tablets with food may be described as an option to help mitigate feelings of an upset stomach or nausea.


Q: Are there any tests required before starting Lonicera?

A: Official documents note that certain health checks, including blood pressure monitoring and a review of medical history, are recommended either prior to or shortly after administration begins. The timing of a full physical examination may be deferred by the clinician.


Q: Is Lonicera suitable for use by people over 65?

A: Official labeling states that this medicine is not indicated for use in elderly (post-menopausal) women. Eligibility for this medication is restricted to women who are of reproductive age.


Q: Does Lonicera affect blood pressure?

A: The use of combined oral contraceptives is associated with an increased risk of elevated blood pressure. Lonicera is contraindicated in women with uncontrolled hypertension (high blood pressure). Regulatory documents highlight the importance of assessing blood pressure status during the use of this medicine.


Q: Can I take Lonicera if I have kidney issues?

A: Regulatory documents note that no specific dose adjustments are established for patients with renal impairment (kidney issues). However, the presence of severe hepatic impairment (liver issues) is listed as an absolute exclusion criteria for use.


Q: Does Lonicera cause sun sensitivity?

A: Regulatory information notes that a skin condition called chloasma (dark skin patches) may occur, especially in women who have a history of it during pregnancy. Official guidance includes a statement recommending that women with this tendency limit their exposure to the sun or ultraviolet radiation.


Q: What kind of studies support the use of Lonicera?

A: Evidence supporting the use of Lonicera includes clinical research such as Randomized Controlled Trials (RCTs) and observational cohort studies. These types of studies are used to measure outcomes such as pregnancy incidence and reported changes in menstrual cycle symptoms.


Q: Why do doctors prescribe Lonicera for a long period?

A: Lonicera is indicated for the prevention of pregnancy in women of reproductive potential. Since contraceptive protection requires continuous, daily coverage, the drug is prescribed for a long period to maintain consistent effectiveness.


Q: What are the early signs that Lonicera is working for me?

A: The primary action of the drug described in official sources is the inhibition of ovulation, which is a mechanism that is not directly observable by the user. An outcome observed in clinical studies is the measurement of a more predictable bleeding schedule.


Q: Does Lonicera cause stomach upset or nausea?

A: Nausea and vomiting are listed among the common adverse reactions reported in the regulatory safety data under the Gastrointestinal disorders System Organ Class.


Q: Why does the packaging for Lonicera include a warning about driving?

A: Official product labeling lists common adverse reactions such as dizziness and headache under Nervous system disorders. Regulatory guidance often advises caution regarding activities requiring full alertness, such as driving or operating machinery, when taking medicines with these effects.


Q: Does Lonicera interfere with birth control pills?

A: Lonicera is a Combined Oral Contraceptive (COC), meaning it is a type of birth control pill itself. Official documents indicate that it is not intended for concurrent use with other hormonal birth control pills.

How should Lonicera be stored and disposed of?

The storage and disposal of Lonicera (Desogestrel and Ethinyl Estradiol tablets) must strictly adhere to the conditions specified in official regulatory labeling to ensure product stability and safety.

Official Storage Conditions

Lonicera must be stored at Controlled Room Temperature (CRT), which is defined as 20 C to 25 C (68 F to 77 F). The product must be kept in its original blister pack until the time of use to ensure protection from excessive heat, light, and moisture. The tablets must not be stored above 30 C (86 F).

Disposal and Safety

Official labeling requires the medication to be kept out of the sight and reach of children to prevent accidental ingestion. Unused or expired Lonicera should be disposed of via a drug take-back program. If no program is available, the product must be mixed with an undesirable substance and placed in a sealed container before being thrown into the household trash. The tablets must not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lonicera found in:

A-Z Index: